Spyre Therapeutics, Inc. SYRE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $97.19M+100% | $85.72M-4.1% | $64.9M-9.3% | $81.66M+79.6% | $48.49M-78.7% | ||
| $644.28M+24.8% | $670.81M+30.6% | $421.3M+23.0% | $444.92M+16.8% | $516.33M+101% | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.7% | $569.77M+16.9% | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.6% | $569.78M+16.9% | ||
| $85.16M+20.5% | $58.69M+8.6% | $46.27M-19.6% | $83.06M+275% | $70.68M+65.1% | ||
| $56.95M-34.7% | $26.68M-70.6% | $49.5M-47.2% | $83.06M+34.7% | $87.17M+6.4% | ||
| 400M0.0% | 400M+3,076,823% | 400M0.0% | 400M0.0% | 400M0.0% | ||
| -$1.2B-17.6% | -$1.13B-16.0% | -$1.07B-16.3% | -$1.05B-24.4% | -$1.02B-25.8% | ||
| $670.81M+39.0% | $715.24M+38.1% | $455.1M+39.0% | $455.77M+21.7% | $482.61M+217% | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.6% | $569.78M+16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
- How much cash does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
- Can Spyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.97 — current assets exceed current liabilities.
- Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.